Gracell Biotechnologies Inc. – NASDAQ:GRCL
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 2 hours
Gracell Biotechnologies stock price monthly change
+2.60%
month
Gracell Biotechnologies stock price quarterly change
+133.18%
quarter
Gracell Biotechnologies stock price yearly change
+372.81%
year
Gracell Biotechnologies key metrics
Market Cap | 989.86M |
Enterprise value | N/A |
P/E | -1.42 |
EV/Sales | N/A |
EV/EBITDA | 1.90 |
Price/Sales | N/A |
Price/Book | 0.59 |
PEG ratio | 0.04 |
EPS | -7.13 |
Revenue | N/A |
EBITDA | -525.18M |
Income | -496.98M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGracell Biotechnologies stock price history
Gracell Biotechnologies stock forecast
Gracell Biotechnologies financial statements
| Dec 2022 | 0 | -130.69M | |
|---|---|---|---|
| Mar 2023 | 0 | -151.72M | |
| Jun 2023 | 0 | -146.93M | |
| Sep 2023 | 0 | -67.62M |
| 2025 | 920K | -57.23M | -6221.34% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-11-13 | -0.26 | -0.1 |
|---|---|---|
| 2024-03-11 | -0.21 | -0.3 |
| Dec 2022 | 1656276000 | 280.51M | 16.94% |
|---|---|---|---|
| Mar 2023 | 1473608000 | 263.07M | 17.85% |
| Jun 2023 | 1377886000 | 241.16M | 17.5% |
| Sep 2023 | 1889957000 | 268.86M | 14.23% |
| Dec 2022 | 0 | 0 | 0 |
|---|---|---|---|
| Mar 2023 | 0 | 0 | 0 |
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | 0 | 0 | 0 |
Gracell Biotechnologies alternative data
| Aug 2023 | 314 |
|---|---|
| Sep 2023 | 314 |
| Oct 2023 | 314 |
| Nov 2023 | 314 |
| Dec 2023 | 314 |
| Jan 2024 | 314 |
| Feb 2024 | 314 |
| Mar 2024 | 314 |
| Apr 2024 | 314 |
| May 2024 | 314 |
| Jun 2024 | 314 |
| Jul 2024 | 314 |
Gracell Biotechnologies other data
4.03%
-4.97%
of GRCL is owned by hedge funds
18
-13
13.62M
-16.81M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q3 2023 13 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 15 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 13 Mar 2023 | Q4 2022 Earnings Call Transcript |
Week In Review: Lee's Pharm Signs $138M Agreement For China Rights To Heart Failure Therapy
Week In Review: $1.7B Collaboration Between Elpiscience And Astellas Is Final 2023 Deal
Week In Review: Tang Capital Offers $465M For LianBio Plus 80% Of Any Licenses/Divestments
Week In Review: Adlai Nortye Stages $97.5 Million U.S. IPO On NASDAQ
Week In Review: BeiGene And BMS Close BeiGene-Celgene PD-1 Partnership
Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement
Week In Review: Structure Stages $161 Million U.S. IPO For AI/Structure-Based Drug Development
Week In Review: China's NMPA Approves Pfizer's Oral COVID-19 Therapy Paxlovid
-
When is Gracell Biotechnologies's next earnings date?
Unfortunately, Gracell Biotechnologies's (GRCL) next earnings date is currently unknown.
-
Does Gracell Biotechnologies pay dividends?
No, Gracell Biotechnologies does not pay dividends.
-
How much money does Gracell Biotechnologies make?
Gracell Biotechnologies has a market capitalization of 989.86M. Gracell Biotechnologies made a loss 607.51M US dollars in net income (profit) last year or -$0.3 on an earnings per share basis.
-
What is Gracell Biotechnologies's stock symbol?
Gracell Biotechnologies Inc. is traded on the NASDAQ under the ticker symbol "GRCL".
-
What is Gracell Biotechnologies's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Gracell Biotechnologies?
Shares of Gracell Biotechnologies can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Gracell Biotechnologies have?
As Jul 2024, Gracell Biotechnologies employs 314 workers.
-
When Gracell Biotechnologies went public?
Gracell Biotechnologies Inc. is publicly traded company for more then 4 years since IPO on 8 Jan 2021.
-
What is Gracell Biotechnologies's official website?
The official website for Gracell Biotechnologies is gracellbio.com.
-
How can i contact Gracell Biotechnologies?
Gracell Biotechnologies can be reached via phone at +86 512 6262 6701.
Gracell Biotechnologies company profile:
Gracell Biotechnologies Inc.
gracellbio.comExchange:
NASDAQ
Full time employees:
314
Industry:
Biotechnology
Sector:
Healthcare
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Building 12, Block B
Suzhou, 215123
Suzhou, 215123
CIK: 0001826492
ISIN: US38406L1035
CUSIP: 38406L103
